• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

勘误：冬凌草甲素通过靶向Akt信号通路使肝癌细胞对索拉非尼的抗癌作用敏感 [更正]

Erratum: Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway [Corrigendum].

出版信息

Cancer Manag Res. 2021 Mar 16;13:2515. doi: 10.2147/CMAR.S310256. eCollection 2021.

DOI:10.2147/CMAR.S310256
PMID:33776476
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7991195/
Abstract

[This corrects the article DOI: 10.2147/CMAR.S257482.].

摘要

[本文更正了文章的数字对象标识符：10.2147/CMAR.S257482。]

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf5c/7991195/6b437f1621e2/CMAR-13-2515-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf5c/7991195/6b437f1621e2/CMAR-13-2515-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf5c/7991195/6b437f1621e2/CMAR-13-2515-g0001.jpg

相似文献

1
Erratum: Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway [Corrigendum].勘误：冬凌草甲素通过靶向Akt信号通路使肝癌细胞对索拉非尼的抗癌作用敏感 [更正]
Cancer Manag Res. 2021 Mar 16;13:2515. doi: 10.2147/CMAR.S310256. eCollection 2021.
2
Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway.冬凌草甲素通过靶向Akt信号通路使肝癌细胞对索拉非尼的抗癌作用敏感化。
Cancer Manag Res. 2020 Sep 7;12:8081-8091. doi: 10.2147/CMAR.S257482. eCollection 2020.
3
Erratum: IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells [Corrigendum].勘误：IL-6/STAT3信号通路通过靶向癌症干细胞导致肝癌对索拉非尼耐药[勘误]。
Onco Targets Ther. 2020 Nov 27;13:12253-12254. doi: 10.2147/OTT.S292577. eCollection 2020.
4
Erratum: Drug-Related Hypertension Associated with the Efficacy of Apatinib on Hepatocellular Carcinoma [Corrigendum].勘误：与阿帕替尼对肝细胞癌疗效相关的药物性高血压[更正]。
Cancer Manag Res. 2020 Jun 3;12:4169-4170. doi: 10.2147/CMAR.S263933. eCollection 2020.
5
Erratum: Suppressing Growth and Invasion of Human Hepatocellular Carcinoma Cells by Celecoxib Through Inhibition of Cyclooxygenase-2 [Corrigendum].勘误：塞来昔布通过抑制环氧合酶-2抑制人肝癌细胞的生长和侵袭[更正]。
Cancer Manag Res. 2021 Nov 8;13:8353-8354. doi: 10.2147/CMAR.S347636. eCollection 2021.
6
Erratum: Glucosamine-6-Phosphate Isomerase 1 Promotes Tumor Progression and Indicates Poor Prognosis in Hepatocellular Carcinoma [Corrigendum].勘误：6-磷酸葡萄糖胺异构酶1促进肿瘤进展并提示肝细胞癌预后不良[更正]。
Cancer Manag Res. 2020 Aug 5;12:6861-6862. doi: 10.2147/CMAR.S273562. eCollection 2020.
7
Erratum: lncRNA TM4SF1-AS1 Activates the PI3K/AKT Signaling Pathway and Promotes the Migration and Invasion of Lung Cancer Cells [Corrigendum].勘误：lncRNA TM4SF1-AS1激活PI3K/AKT信号通路并促进肺癌细胞的迁移和侵袭[更正]。
Cancer Manag Res. 2020 Sep 4;12:8055. doi: 10.2147/CMAR.S278182. eCollection 2020.
8
Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.20(S)-人参皂苷 Rg3 与索拉非尼通过调控 PTEN/Akt 信号通路协同抑制肝癌。
Biomed Pharmacother. 2018 Jan;97:1282-1288. doi: 10.1016/j.biopha.2017.11.006. Epub 2017 Dec 14.
9
Erratum: NECTIN4 Promotes Papillary Thyroid Cancer Cell Proliferation, Migration, and Invasion and Triggers EMT by Activating AKT [Corrigendum].勘误：NECTIN4通过激活AKT促进甲状腺乳头状癌细胞的增殖、迁移和侵袭并引发上皮-间质转化[勘误]。
Cancer Manag Res. 2019 Nov 28;11:10041. doi: 10.2147/CMAR.S239515. eCollection 2019.
10
Erratum: Disulfiram Inhibits Epithelial-Mesenchymal Transition Through TGF-ERK-Snail Pathway Independently of Smad4 to Decrease Oral Squamous Cell Carcinoma Metastasis [Corrigendum].勘误：双硫仑通过TGF-ERK-蜗牛通路抑制上皮-间质转化，独立于Smad4以减少口腔鳞状细胞癌转移[勘误说明]
Cancer Manag Res. 2021 Nov 25;13:8647-8650. doi: 10.2147/CMAR.S348759. eCollection 2021.